Monitor for initiation of clinical dosing and any partnership or funding announcements that could validate the platform. The preclinical data is encouraging but early-stage; the next catalyst is first-patient-dosed or a strategic collaboration.
Price Chart
Executive Summary
Century Therapeutics presented preclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, highlighting scalable production, in vivo function, and immune evasion. The company also updated progress toward clinical dosing. This is an early-stage pipeline update with no regulatory decision or financial data, making it a modest positive for the program's feasibility but not a near-term catalyst.
Key Facts
- CNTY-813 is an iPSC-derived islet replacement therapy for type 1 diabetes
- Data demonstrated scalable production, in vivo function, and immune evasion
- Updated progress toward clinical dosing
Financial Impact
No financial data provided; early-stage preclinical update with no revenue or cost implications disclosed
Risk Factors
- Preclinical data may not translate to clinical success
- No timeline for clinical dosing provided
- Early-stage biotech with no approved products or revenue
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3373783 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 25d ago | 8-K | $1.53 $1.48 | ▼ −3.27% | ▼ −3.94% | $1.45 (−5.23%) |
Oct 2, 2026 25d ago | Press Release | $1.53 $1.48 | ▼ −3.27% | ▼ −3.94% | $1.45 (−5.23%) |
Sep 22, 2026 5w ago | Institutional Cluster | $1.89 $1.76 | ▼ −6.88% | ▼ −6.16% | $1.45 (−23.28%) |
Sep 10, 2026 6w ago | 3 | $1.94 $2.00 | ▲ +3.09% | ▲ +3.54% | $1.45 (−25.26%) |
Aug 12, 2026 10w ago | 8-K | $1.96 $1.93 | ▼ −1.53% | ▼ −2.23% | $1.45 (−26.02%) |
Aug 12, 2026 10w ago | Press Release | $1.96 $1.93 | ▲ +1.53% | ▲ +2.23% | $1.45 (+26.02%) |
Jun 16, 2026 19w ago | 8-K | $2.25 $2.29 | ▲ +1.78% | ▲ +1.00% | $1.45 (−35.56%) |
Jun 15, 2026 19w ago | Insider Cluster | $2.18 $2.25 | ▲ +3.21% | ▲ +4.46% | $1.45 (−33.49%) |
Jun 9, 2026 20w ago | Insider Cluster | $2.12 $2.24 | ▲ +5.66% | ▲ +3.96% | $1.45 (−31.60%) |
Jun 9, 2026 20w ago | Insider Cluster | $2.12 $2.24 | ▲ +5.66% | ▲ +3.96% | $1.45 (−31.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers